GlassScriptPhysician profile
Alexander Molina
NPI 1316142235
$3,023.81
in general payments reported to CMS, 2019-2025
33 companies · $14.57 in 2025
The $14.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $406 · 2022: $51.31 · 2023: $333 · 2024: $389 · 2025: $14.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $528.09 | 2019-2020 | |
| Lilly USA, LLC | $285.23 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $279.77 | 2019-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $258.20 | 2019-2024 | Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $216.38 | 2019-2022 | |
| Abbvie INC. | $212.80 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.77 | 2019-2023 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $114.30 | 2019 | |
| Astellas Pharma US INC | $93.38 | 2019-2024 | Veozah |
| Pfizer INC. | $88.84 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.55 | 2019 | |
| Amarin Pharma, INC. | $68.71 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $58.11 | 2019 | |
| Glaxosmithkline, LLC. | $54.04 | 2019-2025 | Shingrix, Arexvy |
| Corcept Therapeutics | $52.86 | 2023 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.57 | 2024 | |
| Bausch Health US, LLC | $43.79 | 2019-2020 | |
| Abbott Laboratories | $43.46 | 2023-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $39.40 | 2019-2020 | |
| Exact Sciences Corporation | $35.98 | 2023-2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $32.19 | 2019 | |
| Upsher-Smith Laboratories LLC | $32.10 | 2019-2020 | |
| Almatica Pharma LLC | $30.13 | 2023-2024 | Loreev Xr, Gralise |
| Adlon Therapeutics L.P. | $26.63 | 2019-2020 | |
| Assertio Therapeutics, INC. | $25.18 | 2019 | |
| Neos Therapeutics, LP | $18.76 | 2019 | |
| Shire North American Group INC | $17.79 | 2019 | |
| Amgen INC. | $16.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.26 | 2023 | |
| Dexcom, INC. | $14.07 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $10.86 | 2019 | |
| Sunovion Pharmaceuticals INC. | $10.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.